Context Therapeutics (NASDAQ:CNTX – Get Free Report) announced its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01, reports.
Context Therapeutics Price Performance
Shares of NASDAQ CNTX opened at $0.81 on Friday. The stock has a market capitalization of $60.60 million, a price-to-earnings ratio of -0.88 and a beta of 2.06. The business has a 50-day moving average of $0.86 and a 200-day moving average of $1.45. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75.
Wall Street Analysts Forecast Growth
CNTX has been the topic of a number of research reports. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Friday. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities initiated coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $6.17.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- Are Penny Stocks a Good Fit for Your Portfolio?
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- Expert Stock Trading Psychology Tips
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
